NTRBW
Nutriband Inc.
—
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
None
$0.55
$-1.18 (-68.21%)
Price History
52-Week Range
Sign in to add NTRBW to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.51 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -35.10% |
| ROE | -145.72% |
| Debt/Equity | 3.89 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 11.5 |
| Beta | 1.94 |
| SMA 20 | $0.62 |
| SMA 40 | $0.80 |
| 52-Week High | $2.99 |
| 52-Week Low | $0.25 |
| 50-Day Avg | $0.85 |
| 200-Day Avg | $1.35 |
| Avg Volume | 861 |
| Volume | 696 |
Performance Analysis
NEUTRALNTRBW presents a mixed picture with both positive and negative indicators.
~
Trading at 11% of its 52-week range.
+
RSI at 11.5 signals oversold conditions — a bounce may be ahead.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
-
Revenue declined 35.1% year-over-year.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 01, 2026 05:07 UTC
Back to Screener Export Report